TY - JOUR
T1 - Histological evaluation of the effects of angiotensin peptides on wound repair in diabetic mice
AU - Rodgers, Kathleen E.
AU - Roda, Norma
AU - Felix, Juan C.
AU - Espinoza, Theresa
AU - Maldonado, Sonia
AU - DiZerega, Gere
PY - 2003/12
Y1 - 2003/12
N2 - Recent studies have shown that angiotensin peptides accelerate dermal repair. Histological observation of samples taken at the termination of studies showed that the wounds treated with peptides were more mature and organized by day 25 after full thickness excision in diabetic mice. However, the mechanism by which this acceleration occurs has not been determined. In the experiments described here, the effect of angiotensin peptides [AII, A(1-7) and NorLeu3-A(1-7)] on the quality of the healing wound was evaluated histologically. Administration of the peptides accelerated collagen deposition, re-epithelialization and new blood vessel formation. By day 4, the percentage of the wound with collagen increased two- to six-fold depending upon the peptide. The increase by angiotensin peptides continued throughout the experimental period. On days 4 and 7 (only) after injury, exposure to angiotensin peptides increased the number of blood vessels at the wound site two- to three-fold. Finally, the percentage of the wound site covered with new epithelium increased after administration of angiotensin peptides. Re-epithelialization was observed as early as day 4 in wounds treated with angiotensin peptides. The increase was greater at later time points [up to 8-fold at day 14 with NorLeu3-A(1-7)]. Fibroblast infiltration and proliferation occurred earlier in wounds treated with angiotensin peptides. Wounds treated with A(1-7) and NorLeu3-A(1-7) had an increase in neutrophils and macrophages on day 4 after wounding. Overall, administration of these peptides resulted in a healing site that was more mature, including reorganization of the collagen into a basket-weave appearance. Further, these studies confirm the superiority of NorLeu3-A(1-7) to AII and A(1-7) in wound healing evaluated at a microscopic level.
AB - Recent studies have shown that angiotensin peptides accelerate dermal repair. Histological observation of samples taken at the termination of studies showed that the wounds treated with peptides were more mature and organized by day 25 after full thickness excision in diabetic mice. However, the mechanism by which this acceleration occurs has not been determined. In the experiments described here, the effect of angiotensin peptides [AII, A(1-7) and NorLeu3-A(1-7)] on the quality of the healing wound was evaluated histologically. Administration of the peptides accelerated collagen deposition, re-epithelialization and new blood vessel formation. By day 4, the percentage of the wound with collagen increased two- to six-fold depending upon the peptide. The increase by angiotensin peptides continued throughout the experimental period. On days 4 and 7 (only) after injury, exposure to angiotensin peptides increased the number of blood vessels at the wound site two- to three-fold. Finally, the percentage of the wound site covered with new epithelium increased after administration of angiotensin peptides. Re-epithelialization was observed as early as day 4 in wounds treated with angiotensin peptides. The increase was greater at later time points [up to 8-fold at day 14 with NorLeu3-A(1-7)]. Fibroblast infiltration and proliferation occurred earlier in wounds treated with angiotensin peptides. Wounds treated with A(1-7) and NorLeu3-A(1-7) had an increase in neutrophils and macrophages on day 4 after wounding. Overall, administration of these peptides resulted in a healing site that was more mature, including reorganization of the collagen into a basket-weave appearance. Further, these studies confirm the superiority of NorLeu3-A(1-7) to AII and A(1-7) in wound healing evaluated at a microscopic level.
KW - A (1-7)
KW - All
KW - Angiotensin
KW - Diabetic acceleration
KW - Wound healing
UR - http://www.scopus.com/inward/record.url?scp=0347062408&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0347062408&partnerID=8YFLogxK
U2 - 10.1111/j.0906-6705.2003.00087.x
DO - 10.1111/j.0906-6705.2003.00087.x
M3 - Article
C2 - 14714558
AN - SCOPUS:0347062408
SN - 0906-6705
VL - 12
SP - 784
EP - 790
JO - Experimental Dermatology
JF - Experimental Dermatology
IS - 6
ER -